PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
38.07%
Net income growth similar to VET's 39.58%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
-5.43%
Negative yoy D&A while VET is 16.68%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
17.62%
Some yoy growth while VET is negative at -29.61%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
275.00%
SBC growth while VET is negative at -3.23%. John Neff would see competitor possibly controlling share issuance more tightly.
1.72%
Slight usage while VET is negative at -153.26%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
-53.82%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.72%
Some yoy usage while VET is negative at -153.26%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-253.19%
Both negative yoy, with VET at -92.60%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-64.96%
Both yoy CFO lines are negative, with VET at -55.19%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-28.21%
Negative yoy CapEx while VET is 52.93%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-99.34%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
290.96%
Purchases growth of 290.96% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-95.71%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-27.76%
Both yoy lines negative, with VET at -862.50%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-217.12%
We reduce yoy invests while VET stands at 49.71%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
78.13%
We repay more while VET is negative at -23703.48%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.